Similar articles

• Treatment with modified intravesical oxybutynin chloride for neurogenic bladder in children.

  Hayashi A, Saito M, Okada S, Hanada T, Watanabe T, Satoh K, Kanzaki S. Hayashi A, et al. J Pediatr Urol. 2007 Dec;3(6):438-42. doi: 10.1016/j.jpurol.2007.05.007. Epub 2007 Aug 2. J Pediatr Urol. 2007. PMID: 18947791
• Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.

  Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G. Cartwright PC, et al. J Urol. 2009 Oct;182(4):1548-54. doi: 10.1016/j.juro.2009.06.058. Epub 2009 Aug 15. J Urol. 2009. PMID: 19683731 Clinical Trial.
• Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.

  Kennelly MJ, Lemack GE, Foote JE, Trop CS. Kennelly MJ, et al. Urology. 2009 Oct;74(4):741-5. doi: 10.1016/j.urology.2009.05.008. Epub 2009 Jul 22. Urology. 2009. PMID: 19628264
• Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.

  Schmid DM, Roy S, Sulser T, Scheiner D. Schmid DM, et al. BJU Int. 2008 Jul 25;102 Suppl 1:7-10. doi: 10.1111/j.1464-410X.2008.07827.x. BJU Int. 2008. PMID: 18665972 Review.
• Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review.

  Arruda RM, Castro R, Sartori M, Girão MJ. Arruda RM, et al. Curr Opin Obstet Gynecol. 2009 Oct;21(5):412-4. doi: 10.1097/GCO.0b013e32832fd28f. Curr Opin Obstet Gynecol. 2009. PMID: 19593131 Review.